AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30349845 — intervention group
Group type: COMPARATOR
Intervention: Comparator group (nonquinolone)
Number of subjects: 30
Study 30350134 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe periodontitis
Number of subjects: 103
Study 30350134 — intervention group
Group type: EXPERIMENTAL
Intervention: Full mouth probing pocket depth (PPD)
Number of subjects: 103
Study 30350134 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontitis (overall)
Number of subjects: 103
Study 30350134 — intervention group
Group type: COMPARATOR
Intervention: No periodontitis
Number of subjects: 103
Study 30350179 — intervention group
Group type: EXPERIMENTAL
Intervention: Trifluridine/tipiracil (FTD/TPI) 35 mg/m² during a 28-day treatment cycle
Number of subjects: 549
Study 30351341 — intervention group
Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor luminespib (AUY922)
Number of subjects: 29
Study 30351349 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction rule for MRSA transmission to HCWs' gowns
Number of subjects: 0
Study 30351349 — intervention group
Group type: COMPARATOR
Intervention: Current clinical practice (nares surveillance culture for MRSA colonization)
Number of subjects: 0
Study 30351349 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction rule in validation cohort
Number of subjects: 0
Study 30351367 — intervention group
Group type: EXPERIMENTAL
Intervention: AHEI diet quality score
Number of subjects: 30904
Study 30351367 — intervention group
Group type: EXPERIMENTAL
Intervention: AMED diet quality score
Number of subjects: 30904
Study 30351367 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet quality score
Number of subjects: 30904
Study 30351367 — intervention group
Group type: EXPERIMENTAL
Intervention: Central nervous system GRSs
Number of subjects: 30904
Study 30351367 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-central nervous system GRSs
Number of subjects: 30904
Study 30351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemic male infants
Number of subjects: 95
Study 30351381 — intervention group
Group type: COMPARATOR
Intervention: IDA subjects (both sexes)
Number of subjects: 95
Study 30351381 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA male infants
Number of subjects: 95
Study 30351381 — intervention group
Group type: EXPERIMENTAL
Intervention: IDA female infants
Number of subjects: 95
Study 30351381 — intervention group
Group type: EXPERIMENTAL
Intervention: Anemia (both sexes)
Number of subjects: 95
Study 30351387 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (8 km running every second day for 22 days)
Number of subjects: 10
Study 30351428 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral posture during clinical shoulder tests
Number of subjects: 70
Study 30351428 — intervention group
Group type: EXPERIMENTAL
Intervention: Slouched posture during clinical shoulder tests
Number of subjects: 70
Study 30351428 — intervention group
Group type: EXPERIMENTAL
Intervention: Upright posture during clinical shoulder tests
Number of subjects: 70
Study 30351428 — intervention group
Group type: COMPARATOR
Intervention: Neutral posture (control group)
Number of subjects: 70
Study 30351428 — intervention group
Group type: COMPARATOR
Intervention: Slouched posture (control group)
Number of subjects: 70
Study 30351428 — intervention group
Group type: COMPARATOR
Intervention: Upright posture (control group)
Number of subjects: 70
Study 30351999 — intervention group
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Number of subjects: 24
Study 30352437 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate (LaC)
Number of subjects: 2026
Study 30352440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) on
Number of subjects: 18
Study 30352440 — intervention group
Group type: COMPARATOR
Intervention: Cochlear Implant (CI) off
Number of subjects: 18
Study 30352440 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI)
Number of subjects: 18
Study 30352550 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) with a single fraction of 26Gy for tumours ≤4 cm in maximum diameter.
Number of subjects: 70
Study 30352550 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative body radiotherapy (SABR) with 42Gy in three fractions for tumours >4 cm in maximum diameter.
Number of subjects: 70
Study 30352550 — intervention group
Group type: EXPERIMENTAL
Intervention: SABR
Number of subjects: 70
Study 30352576 — intervention group
Group type: EXPERIMENTAL
Intervention: HYP-RT with concomitant CDDP (4 weekly cycles of 35 mg/m2)
Number of subjects: 20
Study 30352576 — intervention group
Group type: EXPERIMENTAL
Intervention: HYP-RT with concomitant CDDP
Number of subjects: 20
Study 30352608 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy
Number of subjects: 21
Study 30352608 — intervention group
Group type: COMPARATOR
Intervention: Concomitant chemo-radiotherapy (reference treatment)
Number of subjects: 21
Study 30352696 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Rating Inventory of Executive Function initiation at 3 months
Number of subjects: 195
Study 30352696 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior Rating Inventory of Executive Function initiation at 12 months
Number of subjects: 195
Study 30352714 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge opioid prescription (median 225mg OMEQ)
Number of subjects: 205
Study 30352714 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdischarge opioid use (median 22.5mg OMEQ)
Number of subjects: 205
Study 30352714 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid disposal practices
Number of subjects: 205
Study 30352714 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribing practices
Number of subjects: 205
Study 30352714 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of surgical approaches (open vs robotic)
Number of subjects: 205
Study 30352912 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral angulation technique (LAT) targeting the anterior superior iliac spine (ASIS)
Number of subjects: 25
Study 30352941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalantercept (0.6 mg/kg subcutaneously every 3 weeks) plus Sorafenib (400 mg orally once daily)
Number of subjects: 21
Study 30352941 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalantercept (0.4 mg/kg subcutaneously every 3 weeks) plus Sorafenib (400 mg orally once daily)
Number of subjects: 21
Study 30353044 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib (Lynparza™) maintenance monotherapy
Number of subjects: 95
Study 30353044 — intervention group
Group type: COMPARATOR
Intervention: No detectable HRR mutations (Control)
Number of subjects: 95
Study 30353380 — intervention group
Group type: COMPARATOR
Intervention: Nondeprived patients (n=177)
Number of subjects: 1834
Study 30353380 — intervention group
Group type: COMPARATOR
Intervention: Deprived patients (n=97)
Number of subjects: 1834
Study 30353380 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort (n=1447)
Number of subjects: 1834
Study 30353380 — intervention group
Group type: COMPARATOR
Intervention: Nondeprived patients
Number of subjects: 1834
Study 30353380 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially deprived patients
Number of subjects: 1834
Study 30353380 — intervention group
Group type: EXPERIMENTAL
Intervention: Survivors
Number of subjects: 1834
Study 30353806 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive airway pressure (PAP) treatment for 4 months
Number of subjects: 198
Study 30353806 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PAP treatment)
Number of subjects: 198
Study 30353806 — intervention group
Group type: EXPERIMENTAL
Intervention: PAP treatment adherence in participants without obesity
Number of subjects: 198
Study 30353813 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep duration
Number of subjects: 92
Study 30353813 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 92
Study 30353817 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported WASO in HxCP group
Number of subjects: 60
Study 30353817 — intervention group
Group type: EXPERIMENTAL
Intervention: Actigraphic WASO in HxCP group
Number of subjects: 60
Study 30353817 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression in HxCP group
Number of subjects: 60
Study 30353817 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported WASO and SE in HxCP group
Number of subjects: 60
Study 30353817 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported WASO and depression in NCP group
Number of subjects: 60
Study 30353817 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily pain in NCP group
Number of subjects: 60
Study 30354232 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete anterior Circle of Willis (COW)
Number of subjects: 482
Study 30354232 — intervention group
Group type: COMPARATOR
Intervention: Unilateral carotid artery stenosis
Number of subjects: 482
Study 30354232 — intervention group
Group type: COMPARATOR
Intervention: Other plaque features
Number of subjects: 482
Study 30354288 — intervention group
Group type: EXPERIMENTAL
Intervention: AI-guided pulmonary vein isolation (PVI) with target values of 550 for anterior and 400 for posterior left atrial regions.
Number of subjects: 40
Study 30354289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-neuromodulation through a right-sided approach
Number of subjects: 20
Study 30354289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardio-neuromodulation
Number of subjects: 20
Study 30354460 — intervention group
Group type: EXPERIMENTAL
Intervention: European Society of Cardiology pathway
Number of subjects: 1935
Study 30354460 — intervention group
Group type: EXPERIMENTAL
Intervention: European Society of Cardiology pathway with HEART score ≤3
Number of subjects: 1935
Study 30354460 — intervention group
Group type: EXPERIMENTAL
Intervention: High-STEACS pathway
Number of subjects: 1935
Study 30354460 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical risk scores with High-STEACS pathway
Number of subjects: 1935
Study 30354556 — intervention group
Group type: EXPERIMENTAL
Intervention: Interatrial shunt device (IASD)
Number of subjects: 64
Study 30354576 — intervention group
Group type: COMPARATOR
Intervention: High-income countries
Number of subjects: 7141
Study 30354576 — intervention group
Group type: COMPARATOR
Intervention: Upper-middle-income countries
Number of subjects: 7141
Study 30354592 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital DAPT
Number of subjects: 3548
Study 30354592 — intervention group
Group type: COMPARATOR
Intervention: In-hospital DAPT
Number of subjects: 3548
Study 30354595 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary PCI in late-presenting patients (12 to 72 hours after symptom onset)
Number of subjects: 865
Study 30354595 — intervention group
Group type: COMPARATOR
Intervention: Primary PCI in early-presenting patients (<12 hours after symptom onset)
Number of subjects: 865
Study 30354636 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon treatment
Number of subjects: 157
Study 30354645 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloon
Number of subjects: 0
Study 30354650 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 891
Study 30354650 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (reference group)
Number of subjects: 891
Study 30354721 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm group
Number of subjects: 92
Study 30354737 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate secondary prevention treatment at discharge (dual antiplatelet therapy and moderate/high dose statins, new-P2Y12 inhibitors, ACE inhibitors/ARBs, beta-blockers as indicated)
Number of subjects: 4169
Study 30354737 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based treatments at discharge
Number of subjects: 4169
Study 30354984 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodine sign
Number of subjects: 91
Study 30354984 — intervention group
Group type: COMPARATOR
Intervention: Spot sign
Number of subjects: 91
Study 30355158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 299v (20 billion CFU) once daily for 6 weeks
Number of subjects: 20
Study 30355158 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin (250 mg QID for 10 days)
Number of subjects: 20
Study 30355199 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest oxLDL/HDL quartile
Number of subjects: 3019
Study 30355199 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 3019
Study 30355285 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask UNIQUE® (LMAU) in correct position
Number of subjects: 202
Study 30355285 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask UNIQUE® (LMAU) in radiologically misplaced position
Number of subjects: 202
Study 30355560 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation Response Resiliency Program for NF
Number of subjects: 55
Study 30355560 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program for NF
Number of subjects: 55
Study 30355563 — intervention group
Group type: EXPERIMENTAL
Intervention: Crush the Crave (CTC)
Number of subjects: 1599
Study 30355563 — intervention group
Group type: COMPARATOR
Intervention: On the Road to Quitting (OnRQ)
Number of subjects: 1599
Study 30355607 — intervention group
Group type: EXPERIMENTAL
Intervention: NODDI (Neurite Orientation Dispersion and Density Imaging)
Number of subjects: 0
Study 30355607 — intervention group
Group type: COMPARATOR
Intervention: Conventional DTI (Diffusion Tensor Imaging)
Number of subjects: 0
Study 30355760 — intervention group
Group type: EXPERIMENTAL
Intervention: AHPV assay
Number of subjects: 10040
Study 30355760 — intervention group
Group type: COMPARATOR
Intervention: HC2 test
Number of subjects: 10040
Study 30355760 — intervention group
Group type: COMPARATOR
Intervention: LBC test
Number of subjects: 10040
Study 30355792 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief contact interventions (BCIs) provided to individuals discharged from the hospital after a suicide attempt, including a crisis card with an emergency number and systematic recontact 6 months later.
Number of subjects: 0
Study 30355792 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional 10-day call for individuals whose index suicide attempt is not the first one.
Number of subjects: 0
Study 30355795 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral feeding during therapeutic hypothermia
Number of subjects: 0
Study 30355795 — intervention group
Group type: COMPARATOR
Intervention: Intravenous dextrose without any parenteral nutrition (PN)
Number of subjects: 0
Study 30355795 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 0
Study 30345376 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocular signs or symptoms observed throughout the study period
Number of subjects: 696
Study 30345376 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence of concurrent systemic disease
Number of subjects: 696
Study 30357273 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic strategy including pretest clinical probability assessment, high-sensitivity D-dimer testing, bilateral lower limb compression ultrasonography (CUS), and computed tomography pulmonary angiography (CTPA)
Number of subjects: 395
Study 30357273 — intervention group
Group type: COMPARATOR
Intervention: Untreated women after exclusion of PE based on negative results on the diagnostic work-up
Number of subjects: 395
Study 30357440 — intervention group
Group type: EXPERIMENTAL
Intervention: First FMT
Number of subjects: 69
Study 30357440 — intervention group
Group type: EXPERIMENTAL
Intervention: Second FMT
Number of subjects: 69
Study 30357467 — intervention group
Group type: EXPERIMENTAL
Intervention: Civilians
Number of subjects: 1725
Study 30357467 — intervention group
Group type: COMPARATOR
Intervention: Combatants
Number of subjects: 1725
Study 30357467 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 1725
Study 30357641 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe depressive symptoms at HIV testing
Number of subjects: 141
Study 30358145 — intervention group
Group type: EXPERIMENTAL
Intervention: Overfeeding (OF)
Number of subjects: 22
Study 30358179 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased dose of nelfinavir during the third trimester
Number of subjects: 18
Study 30358468 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for USH1 and USH2 mutations
Number of subjects: 28
Study 30358468 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing for USH2 mutations
Number of subjects: 28
Study 30358468 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligibility for UshStat® gene therapy
Number of subjects: 28
Study 30358859 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle cell trait genetic variant
Number of subjects: 2658
Study 30358859 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic risk score (GRS) based on 60 variants
Number of subjects: 2658
Study 30358859 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component (PC) factors capturing continental ancestry
Number of subjects: 2658
Study 30359447 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral dose of 2g of azithromycin
Number of subjects: 584
Study 30359447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 584
Study 30359809 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk of obstructive sleep apnea (HR-OSA)
Number of subjects: 144
Study 30359809 — intervention group
Group type: COMPARATOR
Intervention: Low risk of obstructive sleep apnea (LR-OSA)
Number of subjects: 144
Study 30359909 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day) - Cohort 1 (C1)
Number of subjects: 84
Study 30359909 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (1 mg/day) - Cohort 2 (C2)
Number of subjects: 84
Study 30360643 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver status (HIV-positive)
Number of subjects: 446
Study 30360643 — intervention group
Group type: EXPERIMENTAL
Intervention: Low income
Number of subjects: 446
Study 30360643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower social support
Number of subjects: 446
Study 30360643 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower HIV knowledge
Number of subjects: 446
Study 30360643 — intervention group
Group type: EXPERIMENTAL
Intervention: Worse HIV illness perceptions
Number of subjects: 446
Study 30360643 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater perceived HIV stigma
Number of subjects: 446
Study 30361140 — intervention group
Group type: EXPERIMENTAL
Intervention: Track intervention (app-based self-monitoring, dietitian counseling, clinician counseling)
Number of subjects: 351
Study 30361140 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 351
Study 30361153 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior syncope (recurrent syncope)
Number of subjects: 3580
Study 30361153 — intervention group
Group type: COMPARATOR
Intervention: First episode of syncope
Number of subjects: 3580
Study 30361248 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised community physical activity
Number of subjects: 0
Study 30361262 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (400, 800, or 1200 mg daily) combined with decitabine (20 mg/m²)
Number of subjects: 145
Study 30361262 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (400, 800, or 1200 mg daily) combined with azacitidine
Number of subjects: 145
Study 30361296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonists before intervention
Number of subjects: 50
Study 30361296 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa/carbidopa slow-release formulation after 12 weeks
Number of subjects: 50
Study 30361296 — intervention group
Group type: COMPARATOR
Intervention: Control groups (medicated and drug-naive)
Number of subjects: 50
Study 30361296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine agonist withdrawal syndrome
Number of subjects: 50
Study 30361296 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric traits
Number of subjects: 50
Study 30361434 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased regional oxygen extraction fraction ratio in patients with Moyamoya phenomenon
Number of subjects: 35
Study 30361434 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 35
Study 30361858 — intervention group
Group type: COMPARATOR
Intervention: PF-06649751 (0.75 mg, 1.5 mg, 3 mg, 6 mg, 9 mg single dose)
Number of subjects: 63
Study 30361858 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06649751 (5 mg, 15 mg, 25 mg once daily for 21 days)
Number of subjects: 63
Study 30361875 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine 500 mg PO TID (could be reduced to 500 mg QD) and exemestane 25 mg QD or letrozole 2.5 mg QD
Number of subjects: 44
Study 30361875 — intervention group
Group type: EXPERIMENTAL
Intervention: Metronomic capecitabine combined with aromatase inhibitors
Number of subjects: 44
Study 30361959 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Stent Delivery System (MSDS)
Number of subjects: 0
Study 30362288 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF) administered alone
Number of subjects: 0
Study 30362288 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant von Willebrand factor (rVWF) with recombinant factor VIII (rFVIII)
Number of subjects: 0
Study 30362948 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute HCV infection diagnosed at STI clinic (n = 2)
Number of subjects: 10
Study 30362948 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute HCV infection diagnosed by general practitioner (n = 2)
Number of subjects: 10
Study 30362948 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute HCV infection diagnosed by HIV physician (n = 1)
Number of subjects: 10
Study 30362948 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute HCV infection diagnosed at PrEP clinic (n = 5)
Number of subjects: 10
Study 30362948 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected anal intercourse reported by patients (n = 10)
Number of subjects: 10
Study 30362948 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant STI at the time of HCV diagnosis (n = 4)
Number of subjects: 10
Study 30362948 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug use during sex reported (n = 6)
Number of subjects: 10